Publications

Filter by:

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

By:

Manish R. Sharma, MD

Journal: Cell Rep Med.

Published Date: December 22, 2020

An analysis of genetic targets for guiding clinical management of follicular lymphoma

By:

Daniel Morillo, MD

Journal: Expert Rev Hematol.

Published Date: December 4, 2020

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

By:

Irene Moreno, MD, Maria de Miguel, MD

Journal: Lancet Oncology

Published Date: November 1, 2020

Increased vulnerability of clinical research units during the COVID-19 crisis and their protection

By:

Bernard Doger de Speville, MD, PhD, Daniel Morillo, MD, Emiliano Calvo, MD, PhD, Irene Moreno, MD, Maria de Miguel, MD, Tatiana Hernández, MD

Journal: American Cancer Society Journal

Published Date: June 2, 2020

New designs in early clinical drug development

By:

André Mansinho, MD, MSc, Emiliano Calvo, MD, PhD, Maria de Miguel, MD

Journal: Annals of Oncology

Published Date: September 1, 2019

First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers

By:

Amita Patnaik, MD, FRCPC, Drew W. Rasco, MD, Kyriakos P. Papadopoulos, MD, Muralidhar Beeram, MD, MBBS, Nehal Lakhani, MD, PhD, Sreenivasa R. Chandana, MD

Journal: Journal of Clinical Oncology

Published Date: April 20, 2019

A time to build and a time to burn: glucose metabolism for every season.

By:

William B. McKean, MD

Journal: Mol Cell.

Published Date: February 21, 2018

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

By:

Amita Patnaik, MD, FRCPC, Drew W. Rasco, MD, Kyriakos P. Papadopoulos, MD

Journal: Cancer Discovery

Published Date: May 23, 2016

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

By:

Amita Patnaik, MD, FRCPC, Drew W. Rasco, MD, Kyriakos P. Papadopoulos, MD, Lon Smith, MD, M. Beeram, MD

Journal: Clin Cancer Res.

Published Date: May 14, 2015

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

By:

Amita Patnaik, MD, FRCPC, Drew W. Rasco, MD, Kyriakos P. Papadopoulos, MD, Lon Smith, MD, M. Beeram, MD

Journal: Clin Cancer Res.

Published Date: May 14, 2015

Publications

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

An analysis of genetic targets for guiding clinical management of follicular lymphoma

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Increased vulnerability of clinical research units during the COVID-19 crisis and their protection

New designs in early clinical drug development

First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers

A time to build and a time to burn: glucose metabolism for every season.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.